Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Foghorn Therapeutics ( (FHTX) ) has issued an announcement.
On January 9, 2026, Foghorn Therapeutics announced that it had entered into purchase agreements with a group of leading life sciences investors, including BVF Partners, Deerfield Management and Flagship Pioneering, to raise approximately $50 million through the sale of common stock, pre-funded warrants and two series of premium-priced warrants, with the financing priced at a 30% premium to the company’s January 9 closing share price and expected to close on January 13, 2026. The transaction, conducted without an underwriter, strengthens Foghorn’s balance sheet to an estimated $208.9 million in cash, cash equivalents and marketable securities, extending its cash runway into the first half of 2028 and supporting continued advancement of its oncology pipeline, including the Phase 1 dose-escalation trial of FHD-909 (LY4050784) for SMARCA4-mutant cancers, and progression of its selective CBP and EP300 degrader programs toward key IND-related milestones in 2026, which collectively reinforce its positioning as a differentiated player in targeted cancer therapeutics.
The most recent analyst rating on (FHTX) stock is a Buy with a $12.00 price target. To see the full list of analyst forecasts on Foghorn Therapeutics stock, see the FHTX Stock Forecast page.
Spark’s Take on FHTX Stock
According to Spark, TipRanks’ AI Analyst, FHTX is a Neutral.
Foghorn Therapeutics’ overall stock score is primarily impacted by its weak financial performance and unattractive valuation. However, positive corporate events, including strategic partnerships and pipeline updates, provide some optimism for future growth. Technical analysis presents a mixed picture, with no strong trend direction.
To see Spark’s full report on FHTX stock, click here.
More about Foghorn Therapeutics
Foghorn Therapeutics Inc. is a clinical-stage biotechnology company focused on pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression using its Gene Traffic Control platform. The company’s pipeline centers on first-in-class oncology programs, including SMARCA2-targeting agents, selective degraders of CBP and EP300, and other chromatin regulatory targets, with a particular focus on cancers such as non-small cell lung cancer, ER+ breast cancer, hematologic malignancies and other solid tumors with significant unmet medical need.
Average Trading Volume: 215,413
Technical Sentiment Signal: Hold
Current Market Cap: $295.8M
Find detailed analytics on FHTX stock on TipRanks’ Stock Analysis page.